Observational Study of HeartMate 3® Device Data

This observational study, called "Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future," is looking at information from the HeartMate 3® left ventricular assist device (LVAD) in patients. Researchers will connect this device data with real-world health conditions like frailty, GI bleeds, right heart failure, and infections. The goal is to better understand how the device works in patients and predict potential problems. You may be able to join if you are 18 years or older and are scheduled to receive a HeartMate 3® dLVAD. The main thing they are looking at is how long patients survive after 12 months. This study is currently unclear about its recruitment status and plans to include about 150 participants.

Study design
This is an observational study, meaning researchers will analyze existing data from the HeartMate 3® device and patient health records. It aims to enroll about 150 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Survival will be measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06039176

Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future

Recruiting
Not specifiedAges 18+Observational
International Consortium of Circulatory Assist Clinicians
~150 participants
Updated 2025-12-16 on ClinicalTrials.gov
What's tested:HeartMate 3 (R) left ventricular assist device

At a glance

Recruiting sites
4 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Survival
Measured over 12-months
LVAD
Frailty
GI Bleed
Right Heart Failure
Infections
Hypertension
Arrhythmias
Stroke

NCT06039176

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic-Rochester

    Rochester, Minnesotano site contact published

    Recruiting

  • UCSF

    San Francisco, Californiano site contact published

    Recruiting

  • University of Chicago

    Chicago, Illinoisno site contact published

    Recruiting

  • University of Florida

    Gainesville, Floridano site contact published

    Recruiting

  • MUSC

    Charleston, South Carolinano site contact published

    Active, not recruiting

  • University of Kansas Medical Center

    Kansas City, Kansasno site contact published

    Active, not recruiting

  • University of Utah

    Salt Lake City, Utahno site contact published

    Active, not recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Sarah E Schroeder, PhD MSN RN · PRINCIPAL_INVESTIGATOR · International Consortium of Circulatory Assist Clinicians

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Scheduled Heartmate 3 ® dLVAD implantation

Exclusion

\<18 years of age
Scheduled for dLVAD that is NOT a Heartmate 3 (R) device
  • Survival12-months

    12-month survival post LVAD implantation stratified by percentage of abnormal pump data